Original Article
Long non-coding RNA CCAT1 that can be activated by c-Myc promotes pancreatic cancer cell proliferation and migration

Qiuyun Yu, Xinfeng Zhou, Qing Xia, Jia Shen, Jia Yan, Jiuting Zhu, Xiang Li, Ming Shu

Department of Hepatopancreatobiliary Surgery, Ningbo NO.2 Hospital, Ningbo 315010, Zhejiang, China

Received May 3, 2016; Accepted December 14, 2016; Epub December 15, 2016; Published December 30, 2016

Abstract: This study aimed to investigate the potential role of lncRNA CCAT1 in the progression of pancreatic cancer (PC) and to reveal its possible molecular mechanism. The expression of CCAT1 was analyzed in PC tissues and their adjacent normal tissues from patients diagnosed with PC and in two pancreas cancer cell lines, namely PANC-1 and Aspc-1 using real-time polymerase chain reaction (qRT-PCR) and western blot, respectively. The effects of CCAT1 expression on cell proliferation, cell cycle, and migration were analyzed using MTT assay, flow cytometry, and transwell assay, respectively. The effects of c-Myc expression on the expression of CCAT1 and E-box were also analyzed using RNA immunoprecipitation (RIP) and chromatin immunoprecipitation (ChIP) assays, respectively. The results showed that CCAT1 was highly expressed in PC tissues compared to the adjacent tissues (P<0.01) and was also overexpressed in PANC-1 and Aspc-1 cells (P<0.05). The silencing of CCAT1 significantly inhibited cell proliferation and migration (P<0.05), arrested cell cycle at G0/G1 stage, and decreased cyclin D1 expression (P<0.05). An increased expression of c-Myc was observed in the PC tissues compared to the adjacent tissues. We found that suppression of c-Myc altered CCAT1 expression by targeting its promoter at E-box. This study demonstrated that c-Myc-activated CCAT1 may contribute to tumorigenesis and metastasis of PC, which may serve as a potential target for the therapy of PC.

Keywords: Pancreatic cancer, lncRNA CCAT1, cell proliferation, metastasis, c-Myc

Introduction
Pancreatic cancer (PC) remains to be one of the most common digestive system malignancies. It is usually diagnosed at an advanced state, which results in unavailability of effective therapies [1]. Moreover, it is a highly lethal disease with the worst prognosis among all the major malignancies such that the patients with metastatic PC exhibit a five-year survival rate of only 25% [2, 3]. Since 1998, the incidence and mortality rate of PC have been on the rise [4], leading to an estimated 227,000 deaths per year worldwide [5]. Therefore, a better understanding of the molecular mechanisms underlying PC tumorigenesis is the need of the hour to discover novel therapeutic targets for patients with PC.

Recently, some reports have highlighted that non-coding RNAs (ncRNAs) are closely implicated in tumorigenesis [6, 7]. For instance, microRNAs such as miR-1290 and miR-150 have been found to play important roles in PC development and progression [8, 9]. Long non-coding RNAs (IncRNAs) are newly known members of the ncRNA family, which have also been proved to be associated with carcinogenesis and tumor growth in various kinds of tumors, such as cervical, colon, and thyroid cancer [10-13]. Importantly, MALAT1 and HULC, two IncRNAs, have been found to play pivotal roles in the biology of PC [14, 15].

Colon Cancer-Associated Transcript 1 (CCAT1), a recently discovered IncRNA, is located in the vicinity of a well-known transcription factor, c-Myc. Previous studies have revealed that CCAT1 is up-regulated in colon gastric cancer tissues as compared to the normal tissues [16, 17]. However, the role of CCAT1 in PC tumorigenesis is still not well documented and needs to be investigated.
Therefore, in the current study, we investigated the regulation of CCAT1 in PC tissues and cell lines. The effects of CCAT1 on PC cell proliferation, cell migration, cell cycle, and cell migration-associated protein expressions were determined using two types of PC cell lines. In addition, the interaction between CCAT1 and c-Myc was also studied. Thus, the present study aimed to investigate the potential roles of CCAT1 in the PC development and to elucidate the underlying mechanism.

Materials and methods

Patients

A total of 26 PC patients were included in this study, who provided prior informed consents. The PC diagnosis was pathologically confirmed, and cancer tissues and their adjacent normal tissues were obtained from clinically ongoing surgical specimens. Tissues were snap-frozen in liquid nitrogen and stored at -80°C till used for RNA extraction. All procedures in this study were approved by the Human Ethics Committee of Ning Bo NO.2 Hospital.

Cell culture

The human PC cell lines, PANC-1 and Aspc-1 (obtained from the American Type Culture Collection), were cultured in the Dulbecco’s Modified Eagle Medium (DMEM) medium and maintained in a humidified incubator at 37°C with 5% CO₂. The normal pancreatic ductal epithelial cell line HPDE6-C7 (obtained from the American Type Culture Collection) was grown in keratinocyte growth medium (KGM) (Invitrogen, Carlsbad, CA, USA) supplemented with human epidermal growth factor and bovine pituitary extract.

Table 1. The primers used for targets amplification

<table>
<thead>
<tr>
<th>Name</th>
<th>Forward primer</th>
<th>Reverse primer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCAT1</td>
<td>CATTGGGAAAGGTGCCGAGA</td>
<td>ACGCTTAGCCATACAGAGCC</td>
</tr>
<tr>
<td>C-myc</td>
<td>CCACAGCAAACCTCTCACA</td>
<td>TCCAACTTGACCCCTCTGGA</td>
</tr>
<tr>
<td>Cyclin D1</td>
<td>CAATGGGAGCTGCTCTGGTG</td>
<td>TCTGATCTGCTCTGCGAGG</td>
</tr>
<tr>
<td>Cyclin E1</td>
<td>CCTCCAAGGTGCACAGATT</td>
<td>GGACGCACAGGTCTAGAAGC</td>
</tr>
<tr>
<td>Cyclin A1</td>
<td>CAAGGTCCTGAGTTGCTCA</td>
<td>CCCATGTCAGAGAGAGCATT</td>
</tr>
<tr>
<td>E-cadherin</td>
<td>AAGCGATTGCCACATACAC</td>
<td>AAGGATTGCCACATACAC</td>
</tr>
<tr>
<td>N-cadherin</td>
<td>AACTCCAGGGGACCTTTTC</td>
<td>CAAATGAAACCGGGCTATC</td>
</tr>
<tr>
<td>Vimentin</td>
<td>TCCAAGTGTGCTGACCTCTC</td>
<td>TCAACGGCAAAATTCTCCTTC</td>
</tr>
<tr>
<td>GAPDH</td>
<td>GGAGGCCCAAAGGGTCAT</td>
<td>GAGTCTTCCACAGATACCA</td>
</tr>
</tbody>
</table>

RNA isolation and qRT-PCR

Total RNA from cancer tissues and cells was extracted using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA). After treatment with RNase-free DNase I (Promega Biotech, USA), 0.5 μg/μL purified RNA was reverse-transcribed into cDNA with the PrimeScript 1st strand cDNA Synthesis Kit (Invitrogen, Carlsbad, CA, USA). The expression of targets in tissues or cells was measured in an Eppendorf Mastercycler (Brinkman Instruments, Westbury, NY) using the SYBR ExScript qRT-PCR Kit (Takara, China) at a final volume of 20 μL with a standard protocol. Each reaction was performed in triplicate, and the 2-ΔΔCT method was used to determine the relative gene expression level. Melting curves of amplified products were analyzed at the end of each PCR to confirm that only one product was amplified and detected. Phosphoglyceraldehyde dehydrogenase (GAPDH) was chosen as the internal control. Primers used for amplification of targets are shown in Table 1.

Western blot analysis

Cells were lysed in RIPA lysis and extraction buffer (Sangon Biotech, Shanghai, China). The supernatant was collected for the measurement of protein concentration using BCA protein assay kit (Pierce, Rochford, IL, USA). Then 20 μg of protein per cell lysate was subjected to a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and subse-
sequently transferred to the polyvinylidene fluoride (PVDF) membrane (Millipore, Bedford, MA, USA). The membrane was blocked with Tris Buffered Saline-Tween (TBST) containing 5% non-fat milk at room temperature for 1 h. After incubation with antibodies specific for c-Myc, cyclin D1, cyclin E1, cyclin A1, E-cadherin, N-cadherin, and vimentin (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA, USA), the membrane was incubated with horseradish peroxidase-labeled goat anti-rat secondary antibody (1:1000). Then the PVDF membrane was washed three times with 1 × TBST buffer and visualized with an enhanced chemiluminescence method. GAPDH served as the internal control.

**Cell proliferation assay**

Cell proliferation was assessed using MTT (3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyltetrazolium bromide) assay. Cells were seeded in 96-well culture plates at a density of $5 \times 10^3$ cells per well. Each group had five repeats. Then 20 μL of 10 mg/mL MTT was added to each well, followed by incubation for 3 h at 37°C. Then 150 μL of dimethyl sulfoxide (DMSO) was added to each well, and the optical density was measured at 590 nm using a Multiskan EX (Thermo, Vantaa, Finland).

**Clonogenic assay**

The clonogenic assay was performed according to a previously published method [18] with a modification. Briefly, after transfection, cells were plated into 6-cm tissue culture dishes in triplicate at a density of 100 cells/dish. The cells were grown in RPMI-1640 medium containing 10% fetal bovine serum (FBS) for 14 days. The cells were then fixed and stained with Diff-Quick. After air-drying, colonies were counted under the microscope, and at least 30 cells were included in each colony.

**Cell cycle assay**

After transfection, the cells were cultured in RPMI-1640 containing 10% FBS for another 48 h. The cells were then seeded into 6-cm dishes until the concentration reached 80%. The cells were washed with ice-cold PBS followed by fixation with methanol at 4°C for 30 min. The cells were then stained with propidium iodide solution for 30 min. Finally, cell cycle and DNA content were analyzed using flow cytometry.

**Cell migration assay**

The cell migration was determined using wound healing assay. The cells were cultured in 6-well plates at a density of $5 \times 10^5$ cells per well. After the formation of a confluent monolayer, a wound was made across the well with a 200-μL pipette tip. The wound was photographed immediately and the migration of cells across the gap wound was observed using an inverted microscope ($\times 10$ magnification). The width of the gap was detected in five different visual fields, and the average width was calculated.

**RNA immunoprecipitation assay**

RNA immunoprecipitation (RIP) assay was conducted using Magna RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore, Massachusetts, USA) following the manufacturer’s instructions. Anti-c-Myc antibody (BD Biosciences, San Jose, CA, USA) and IgG (control) were used for RIP. Co-precipitated RNAs were detected by qRT-PCR analysis. Total RNAs (input controls) and isotype controls were detected to demonstrate that the detected signals were the results of RNAs specifically binding to the E-box.

**Chromatin immunoprecipitation assay**

Chromatin immunoprecipitation (ChIP) assay was performed using an EZ-ChIP Chromatin Immunoprecipitation Kit (Millipore, Massachusetts, USA) according to the manufacturer's protocol. Cross-linked chromatin was sonicated to obtain 200 bp to 1000 bp fragments. The chromatin was immunoprecipitated using anti-c-Myc antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Normal mouse immunoglobulin G was used as the negative control. Quantitative PCR was conducted using SYBR Green Mix (Roche, Mannheim, Germany) to quantify ChIP-derived DNA.

**Statistical analysis**

The statistical analyses were carried out using Graph Prism 5.0 software (GraphPad Prism, San Diego, CA). The data were expressed as mean ± standard deviation (SD). Independent samples t-test was used for the calculation of significance of paired data. Post-hoc Tukey’s test was employed to calculate the difference among groups. P<0.05 was considered as statistically significant.
Results

**CCAT1 was up-regulated in PC tissues and cells**

To determine whether CCAT1 was dysregulated in PC, we examined the expression levels of CCAT1 in PC tissues and pair-matched adjacent normal pancreatic tissues, as well as PC cells and normal pancreatic cells using qRT-PCR. As presented in Figure 1A, CCAT1 expression was significantly increased in PC tissues in comparison with the adjacent normal pancreatic tissues (P<0.01). Additionally, the expression levels of CCAT1 in PC cells (PANC-1 and Aspec-1) were significantly higher than that in normal pancreatic cells (HPDE6-C7) (P<0.05).

**siRNA-CCAT1 inhibited cell proliferation**

The expression of CCAT1 decreased significantly after transfection with siRNA-CCAT1 in two types of PC cells (Figure 2A). To investigate the effects of CCAT1 on cell proliferation, we performed MTT assays which revealed that suppression of CCAT1 expression by si-CCAT1 could inhibit cell viability of PANC-1 and Aspec-1 cells significantly (P<0.05) (Figure 2B). In accordance with the results of MTT assay, the colony-formation assays showed that clonogenic survival was significantly decreased in PANC-1 and Aspec-1 cells after CCAT1 suppression (P<0.01) (Figure 2C and 2D).

**CCAT1 expression modulated cell cycle**

In order to explore the mechanism of CCAT1 suppression-mediated regulation of PC cell proliferation, flow cytometry was employed to study the cellular DNA content and cell cycle profile. As shown in Figure 3A, the percentage of cells at G0/G1 stage was significantly increased when cells (PANC-1 and Aspc-1) were transfected with siRNA-CCAT1 (P<0.05) suggesting a possible arrest at G0/G1 stage after the suppression of CCAT1.

To determine whether depletion of CCAT1 arrested the cell cycle in the G0/G1 stage, mRNA and protein expression levels of cell cycle-related proteins, including cyclin D1, cyclin E1, and cyclin A1 were analyzed. As presented in Figure 3B and 3C, the expression of cyclin D1 drastically decreased in the siRNA-CCAT1 group compared with that in the control group (P<0.05). However, the expression levels of cyclin A1 and E1 did not change significantly in the two groups.

**siRNA-CCAT1 inhibited cell migration**

In order to investigate the role of CCAT1 in regulating PC cancer cell migration, we performed wound healing assay. The results showed that suppression of CCAT1 significantly inhibited the migration of PANC-1 and Aspc-1 cells compared with controls (P<0.05) (Figure 4A and 4B).

Further studies demonstrated that the expression levels of epithelial-mesenchymal transition (EMT) markers, including E-cadherin, N-cadherin, and vimentin changed significantly before and after CCAT1 suppression. As shown in Figure 4C and 4D, the expression of E-
Figure 2. The mRNA expression of lncRNA CCAT1 in pancreatic cancer cells after transfection with si-CCAT1 (A); lncRNA CCAT1 suppression significantly inhibited the cells proliferation of two types of pancreatic cancer cells assayed by MTT assay (B); lncRNA CCAT1 suppression significantly decreased the number of pancreatic cancer cell colonies assayed by clonogenic assay (C and D). *: P<0.05, **: P<0.01.
Cadmherin increased significantly in the siRNA-CCAT1 group compared with the control group (P<0.01). On the contrary, the expression of N-cadherin and vimentin decreased significantly when cells were transfected with siRNA-CCAT1 (P<0.05) (Figure 3).

CCAT1 is up-regulated by c-Myc through binding to E-box

It has been suggested that c-Myc is overexpressed in PC [19, 20]. In this study, the mRNA and protein expression levels of c-Myc in PC tissues were found to be significantly higher than that in the adjacent normal pancreatic tissues (P<0.01) (Figure 5A). After PC cells were transfected with siRNA-c-Myc, mRNA and protein expressions of c-Myc decreased significantly in the two PC cell lines (P<0.01). Additionally, the expression of CCAT1 significantly decreased (P<0.01) (Figure 5B). In order to explore further the interaction between CCAT1 and c-Myc, we conducted RIP assay in ANC-1 and Aspc-1 cells. The results showed that endogenous E-box was highly

---

**Figure 3.** The role of lncRNA CCAT1 suppression on pancreatic cancer cell cycle. (A) Flow cytometry showed that lncRNA CCAT1 suppression significantly increased the percentage of the two cancer cell lines in G0/G1 stage; (B and C) qRT-PCR (B) and western blot analysis (C) showed that lncRNA CCAT1 suppression significantly decreased cyclin D1 expression, but had no significant effect on cyclin E1 and A1 expressions in the two pancreatic cancer cell lines. *: P<0.05, **: P<0.01.
enriched by c-Myc RIP compared to IgG RIP (Figure 5C), indicating that c-Myc may bind to E-box. To determine whether c-Myc directly binds to the E-box element and contribute to the overexpression of CCAT1, we performed ChIP assay. The result showed that the c-Myc immunoprecipitates were highly enriched in the promoter region of CCAT1 containing the E-box element compared with control IgG immunoprecipitates in PANC-1 and Aspc-1 cells. The CCAT1 promoter with silenced E-box site displayed no significant enrichment (Figure 5D).
IncRNA CCAT1 in pancreatic cancer

Figure 5. c-Myc bound to the promoter regions of IncRNA CCAT1 and regulated its expression. A: mRNA and protein expressions of c-myc in pancreatic cancer tissues and cell lines assayed by qRT-PCR and western blot analysis; B: The effects of c-myc suppression on mRNA and protein expressions of IncRNA CCAT1; C: RNA immunoprecipitation (RIP) assay showing that endogenous E-box was highly enriched by c-myc RIP compared to IgG RIP; D: Chromatin immunoprecipitation (ChIP) assay showed that c-myc immunoprecipitates were highly enriched in promoter region of CCAT1 containing E-box element compared with that without E-box. IgG indicated the negative control of immunoprecipitation. *: P<0.05, **: P<0.01.

Figure 6. The regulatory mechanism of IncRNA CCAT1 in pancreatic cancer.

Discussion

Recently, large-scale gene expression studies have revealed that IncRNAs were dysregulated in many human cancers [21, 22]. Many studies showed that IncRNA CCAT1 may serve as a possible candidate for exploring the regulatory mechanism of CCAT1 in PC is shown in Figure 6. mechanisms in cancers. However, only a few studies have reported the potential role of CC-
AT1 in PC [16, 17]. The data of the present study showed that CCAT1 was significantly upregulated in PC tissues and cancer cells. CCAT1 suppression significantly inhibited cell proliferation and migration in two PC cell lines. Besides, CCAT1 suppression arrested the cell cycle at the G0/G1 stage and significantly decreased the expression of cyclin D1 in PC cells. Moreover, c-Myc was also found to be overexpressed in PC tissues and cells, and silencing of c-Myc altered CCAT1 expression by targeting its promoter at E-box. However, all of these results need to be further discussed.

In previous studies, overexpression of CCAT1 has been shown to be associated with the development of several cancers, such as colon, gastric, and gallbladder cancers [16, 17, 23]. In accordance with the above findings, we also observed that CCAT1 was significantly upregulated in PC tissues, as well as in the two PC cell lines. Therefore, we speculate that the overexpression of CCAT1 may be correlated with the pathogenesis of PC.

We then analyzed the effects of CCAT1 expression on PC cell proliferation using siRNA-mediated gene silencing. Yang et al. [24] suggested that the silencing of CCAT1 inhibits cell proliferation in gastric cancer. In agreement with the above result, our study showed that PC cell proliferation was significantly suppressed after siRNA-mediated depletion of CCAT1, indicating that CCAT1 could promote PC cell proliferation. Additionally, we analyzed the effects of CCAT1 expression on PC cell cycle and cell cycle-associated protein expressions to explore further the mechanism of CCAT1 suppression regulating PC cell proliferation. We found that PC cell cycle was arrested at the G0/G1 stage after CCAT1 suppression, and the expression of cyclin D1 decreased significantly. Increasing the number of evidence support a central role of cyclin D1 in promoting cancer cell proliferation [25]. Importantly, cyclin D1 has been considered as a “pivotal element” of malignant transformation in human cancer, including PC [26]. Taken together, our results corroborated the role of CCAT1 in regulating PC cell proliferation.

Accumulating evidence has demonstrated that epithelial-mesenchymal transition (EMT) is an important biological process contributing to the progression of primary tumors towards metastasis [27]. The expression of E-cadherin, one of EMT markers, was found to be lower in PC tissues than in non-tumor tissues [28]. Two other EMT markers, namely N-cadherin and vimentin were found to be overexpressed in PC [29, 30]. In this study, we found that E-cadherin expression increased significantly, whereas the expressions of N-cadherin and vimentin decreased significantly when PANC-1 and Aspc-1 cells were transfected with siRNA-CCAT1, suggesting the role of CCAT1 in modulating tumor metastasis of PC.

c-Myc is a transcription factor that is generally recognized as an important regulator of cell cycle, proliferation, differentiation, and apoptosis [31, 32]. It has been found to be overexpressed in PC [19, 20] and to promote CCAT1 transcription and regulate CCAT1 expression in colon cancer cells [33]. Importantly, Yang et al. [17] revealed that c-Myc regulates the expression of CCAT1 by directly binding to the E-box. Interestingly, the current study also found that c-Myc could activate CCAT1 expression through interaction with the E-box in the CCAT1 promoter region. Besides, c-Myc knockdown decreased the expression of CCAT1. Thus, the current study further supported the regulatory effects of c-Myc on CCAT1 expression.

In conclusion, our study indicates that upregulated IncRNA CCAT1 is a tumor promoter, which may promote the progression of PC. Moreover, CCAT1 may be activated by transcription factor c-Myc by directly binding to its promoter region (E-box). These findings implicate that IncRNA CCAT1 may serve as an important target in PC therapy. However, further studies are still required to confirm these findings and reveal the potential molecular mechanism for CCAT1 in regulating PC.

Acknowledgements

This study was supported by the Zhejiang Provincial Natural Science Foundation of China (Grant No: Y2080096) and the Medical and Health Science Research Fund of Zhejiang Provincial Health Department (Grant No: 2007A172).

Disclosure of conflict of interest

None.
IncRNA CCAT1 in pancreatic cancer

Address correspondence to: Ming Shu, Department of Hepatobiliary Surgery, Ningbo No.2 Hospital, No.41 North West Street, Ningbo 315010, Zhejiang, China. E-mail: mingshu09@126.com

References


distinct molecular subtypes of colorectal cancer with clinical relevance. Mol Oncol 2014; 8: 1393-1403.


